Characterization of Local Vascular Effects of LNMMA

This study has been completed.

Sponsored by:	Dresden University of Technology
Information provided by:	Dresden University of Technology
ClinicalTrials.gov Identifier:	NCT00180063

Purpose

Characterization of an unexpected venodilative effect of higher L-NMMA-doses in dorsal human hand veins.

Condition	Intervention
Healthy Subjects	Drug: L-NMMA(drug)

Drug Information available for: omega-N-Methylarginine

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Active Control, Crossover Assignment, Efficacy Study

Further study details as provided by Dresden University of Technology:

Study Start Date:	October 2003
Estimated Study Completion Date:	September 2005

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00180063

Locations

Germany
Institute of Clinical Pharmacology, Medical Faculty, University of Technology
Dresden, Germany, 01307

Sponsors and Collaborators

Dresden University of Technology

Investigators

Study Chair:

Wilhelm Kirch, MD

Institute of Clinical Pharmacology

More Information

Study ID Numbers:	IKPD 01-02 Amend LNMMA
Study First Received:	September 9, 2005
Last Updated:	November 1, 2005
ClinicalTrials.gov Identifier:	NCT00180063
Health Authority:	Germany: Federal Institute for Drugs and Medical Devices

Study placed in the following topic categories:

Omega-N-Methylarginine
Healthy

ClinicalTrials.gov processed this record on January 16, 2009